[go: up one dir, main page]

EA201491617A1 - Соединения для лечения спинальной мышечной атрофии - Google Patents

Соединения для лечения спинальной мышечной атрофии

Info

Publication number
EA201491617A1
EA201491617A1 EA201491617A EA201491617A EA201491617A1 EA 201491617 A1 EA201491617 A1 EA 201491617A1 EA 201491617 A EA201491617 A EA 201491617A EA 201491617 A EA201491617 A EA 201491617A EA 201491617 A1 EA201491617 A1 EA 201491617A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
muscular atrophy
spinal muscular
connections
spinal
Prior art date
Application number
EA201491617A
Other languages
English (en)
Other versions
EA029155B1 (ru
Inventor
Чан-Сун Ли
Соонгиу Чой
Гари Митчелл Карп
Хироо Кояма
Хасан Ратни
Original Assignee
ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ПиТиСи ТЕРАПЬЮТИКС, ИНК., Ф. Хоффманн-Ля Рош Аг filed Critical ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Publication of EA201491617A1 publication Critical patent/EA201491617A1/ru
Publication of EA029155B1 publication Critical patent/EA029155B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В настоящей заявке предложены соединения, композиции на их основе и их применение при лечении спинальной мышечной атрофии.
EA201491617A 2012-03-01 2013-02-28 Соединения для лечения спинальной мышечной атрофии EA029155B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261605487P 2012-03-01 2012-03-01
PCT/US2013/028131 WO2013130689A1 (en) 2012-03-01 2013-02-28 Compounds for treating spinal muscular atrophy

Publications (2)

Publication Number Publication Date
EA201491617A1 true EA201491617A1 (ru) 2015-01-30
EA029155B1 EA029155B1 (ru) 2018-02-28

Family

ID=49083256

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491617A EA029155B1 (ru) 2012-03-01 2013-02-28 Соединения для лечения спинальной мышечной атрофии

Country Status (10)

Country Link
US (1) US9371336B2 (ru)
EP (1) EP2819519B1 (ru)
JP (1) JP6092264B2 (ru)
KR (1) KR102099997B1 (ru)
CN (1) CN104302181B (ru)
BR (1) BR112014021531B1 (ru)
CA (1) CA2865957C (ru)
EA (1) EA029155B1 (ru)
MX (1) MX352962B (ru)
WO (1) WO2013130689A1 (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102057351B1 (ko) 2011-12-30 2019-12-18 피티씨 테라퓨틱스, 인크. 척수성 근위축증을 치료하기 위한 화합물
MX357834B (es) 2012-01-26 2018-07-26 Ptc Therapeutics Inc Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal.
PE20142364A1 (es) 2012-02-10 2015-01-10 Hoffmann La Roche Compuestos para tratar atrofia muscular espinal
WO2013142236A1 (en) 2012-03-23 2013-09-26 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
SG11201504933WA (en) * 2012-12-24 2015-07-30 Univ Ramot Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same
EP3035935B1 (en) 2013-08-19 2020-03-11 F. Hoffmann-La Roche AG Compounds for use in the prophylaxis and treatment of cancer
EP3082820B1 (en) 2013-12-19 2022-07-20 PTC Therapeutics, Inc. Methods for modulating the amount of rna transcripts
WO2016196386A1 (en) 2015-05-30 2016-12-08 Ptc Therapeutics, Inc. Methods for modulating rna splicing
EP3133065A1 (en) 2015-08-21 2017-02-22 Merck Patent GmbH Compounds for optically active devices
EA201800367A1 (ru) 2015-12-10 2019-02-28 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения болезни хантингтона
AU2017363369A1 (en) 2016-11-28 2019-05-30 Ptc Therapeutics, Inc Methods for modulating RNA splicing
EP3363793A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Hydrophobic compounds for optically active devices
EP3363786A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Compounds for optically active devices
BR112019025740A2 (pt) 2017-06-05 2020-06-23 Ptc Therapeutics, Inc. Compostos para tratar a doença de huntington
US11608501B2 (en) 2017-06-14 2023-03-21 Ptc Therapeutics, Inc. Methods for modifying RNA splicing
US11382918B2 (en) 2017-06-28 2022-07-12 Ptc Therapeutics, Inc. Methods for treating Huntington's Disease
MX2019015580A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
GB2587457B (en) 2017-08-04 2022-06-01 Skyhawk Therapeutics Inc Methods and compositions for modulating splicing
JP7399870B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
IL279786B2 (en) 2018-06-27 2025-02-01 Reborna Biosciences Inc Preventive or therapeutic agent for spinal muscular atrophy
WO2020005873A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
AU2019294482B2 (en) 2018-06-27 2022-09-01 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
CN118812532A (zh) 2019-02-05 2024-10-22 斯基霍克疗法公司 用于调节剪接的方法和组合物
CN113677344A (zh) 2019-02-06 2021-11-19 斯基霍克疗法公司 用于调节剪接的方法和组合物
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
CN111116460A (zh) * 2019-12-31 2020-05-08 阿里生物新材料（常州）有限公司 一种2-氯-4-羟基吡啶-3-甲醛氢溴酸盐的合成方法
CN115836075A (zh) 2020-05-20 2023-03-21 爱尔兰眼力健公司 用于在光学活性装置中使用的氮杂香豆素和氮杂硫代香豆素衍生物
US20250066377A1 (en) * 2021-12-17 2025-02-27 Pretzel Therapeutics, Inc. Amino chromen-2-one modulators of polrmt
WO2024251925A1 (en) * 2023-06-09 2024-12-12 F. Hoffmann-La Roche Ag Inducible gene expression system

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558618A (en) 1968-04-01 1971-01-26 Dow Chemical Co Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones
US4122274A (en) 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
US4342870A (en) 1980-03-28 1982-08-03 Janssen Pharmaceutica N.V. Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
US5089633A (en) 1987-04-28 1992-02-18 Georgia Tech Research Corporation Substituted isocoumarins
US5726182A (en) 1990-05-02 1998-03-10 Abbott Laboratories Quinolizinone type compounds
AU4231293A (en) 1992-05-13 1993-12-13 E.I. Du Pont De Nemours And Company Substituted pyrido(1,2-A)pyrimidinone derivatives as fungicides
US5597922A (en) 1994-07-29 1997-01-28 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Glycine receptor antagonist pharmacophore
US6630488B1 (en) 1998-09-21 2003-10-07 Biochem Pharma, Inc. Quinolizinones as integrin inhibitors
AU2001230426C1 (en) 2000-01-24 2006-06-22 Astrazeneca Ab Therapeutic morpholino-substituted compounds
GB0205281D0 (en) * 2002-03-06 2002-04-17 Novartis Ag Organic compounds
AU2003237492A1 (en) 2002-06-10 2003-12-22 Acadia Pharmaceuticals Inc. Urotensin ii receptor modulators
WO2004047766A2 (en) 2002-11-25 2004-06-10 Kaloidis Antonia C Treatment for sma disease
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
CN1809563A (zh) 2003-06-20 2006-07-26 希龙公司 吡啶并[1,2－a]嘧啶－4－酮化合物用作抗癌药
US20050046698A1 (en) * 2003-09-02 2005-03-03 Knight Andrew Frederick System and method for producing a selectable view of an object space
CA2545340A1 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Fused heterocyclic compounds
CA2563669A1 (en) 2004-05-04 2005-11-10 Warner-Lambert Company Llc Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents
WO2006045010A2 (en) 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
WO2006078834A1 (en) 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
US8337941B2 (en) 2006-07-27 2012-12-25 The Trustees Of Columbia University In The City Of New York Fluorescent substrates for monoamine transporters as optical false neurotransmitters
AU2008304231A1 (en) * 2007-09-27 2009-04-02 Albany Molecular Research, Inc. Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
US8633019B2 (en) 2008-05-27 2014-01-21 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
US8986935B2 (en) 2008-08-13 2015-03-24 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
WO2011062853A1 (en) 2009-11-20 2011-05-26 Merck Sharp & Dohme Corp. Quinolizidinone carboxamide m1 receptor positive allosteric modulators
WO2011085990A1 (en) 2010-01-13 2011-07-21 Institut Pasteur Korea Anti - infective pyrido (1,2 -a) pyrimidines
KR102057351B1 (ko) 2011-12-30 2019-12-18 피티씨 테라퓨틱스, 인크. 척수성 근위축증을 치료하기 위한 화합물
MX357834B (es) 2012-01-26 2018-07-26 Ptc Therapeutics Inc Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal.
PE20142364A1 (es) 2012-02-10 2015-01-10 Hoffmann La Roche Compuestos para tratar atrofia muscular espinal
WO2013142236A1 (en) 2012-03-23 2013-09-26 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy

Also Published As

Publication number Publication date
CN104302181B (zh) 2017-09-15
JP2015509956A (ja) 2015-04-02
EA029155B1 (ru) 2018-02-28
EP2819519A1 (en) 2015-01-07
CA2865957A1 (en) 2013-09-06
JP6092264B2 (ja) 2017-03-08
MX2014010406A (es) 2015-03-10
MX352962B (es) 2017-12-15
CN104302181A (zh) 2015-01-21
BR112014021531A2 (pt) 2017-06-20
US20150166575A1 (en) 2015-06-18
EP2819519A4 (en) 2015-09-02
US9371336B2 (en) 2016-06-21
EP2819519B1 (en) 2019-10-23
CA2865957C (en) 2020-02-11
HK1200056A1 (en) 2015-07-31
KR102099997B1 (ko) 2020-04-13
BR112014021531A8 (pt) 2021-06-15
KR20140131384A (ko) 2014-11-12
BR112014021531B1 (pt) 2022-10-04
WO2013130689A1 (en) 2013-09-06

Similar Documents

Publication Publication Date Title
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201792465A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201890754A1 (ru) Соединения и способы их применения
EA201590997A1 (ru) Соединения и способы их применения
EA201791007A3 (ru) Соединения и их применения для модуляции гемоглобина
EA201591426A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201591432A1 (ru) Соединения и их применения для модуляции гемоглобина
EA202193044A2 (ru) Способы лечения таупатии
EA201201357A1 (ru) Антитела к cd40
EA201591427A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201400579A1 (ru) Антитела к il-36r
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201400178A1 (ru) Лечение рака молочной железы
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
EA201992707A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201290642A1 (ru) Соединения и способы
WO2015084883A3 (en) Compositions and methods for treating osteoarthritis
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
EA201491522A1 (ru) Способы лечения нарушения походки и/или равновесия у пациентов с рассеянным склерозом с использованием аминопиридина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM